• Home
  • NEW DAY MEDICINE
  • 2 (88) 2026
  • 41 -2 (88) 2026 - Zhabborova M.A., Akhmadzhonova G.M. - MOLECULAR AND PATHOGENETIC ASPECTS OF HIF-1Α INVOLVEMENT IN THE DEVELOPMENT OF INTRAPARTUM FETAL DEATH IN PREECLAMPSIA

41 -2 (88) 2026 - Zhabborova M.A., Akhmadzhonova G.M. - MOLECULAR AND PATHOGENETIC ASPECTS OF HIF-1Α INVOLVEMENT IN THE DEVELOPMENT OF INTRAPARTUM FETAL DEATH IN PREECLAMPSIA

MOLECULAR AND PATHOGENETIC ASPECTS OF HIF-1Α INVOLVEMENT IN THE DEVELOPMENT OF INTRAPARTUM FETAL DEATH IN PREECLAMPSIA

Zhabborova M.A. - Fergana regional branch of the Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health

Akhmadzhonova G.M. - Fergana regional branch of the Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health

Resume

The aim of the study was to evaluate the role of hypoxia-induced factor HIF-1α in the development of fetoplacental insufficiency and intrapartum fetal death in preeclampsia. Materials and methods. The study included a comprehensive analysis of molecular genetic parameters in comparison with Doppler parameters of fetoplacental blood flow. Results. It has been established that HIF-1α overexpression is associated with activation of endothelial cell apoptosis, decreased angiogenesis, and significant abnormalities in Doppler indices preceding the development of acute intrapartum fetal hypoxia in preeclampsia. Conclusion. These data suggest that HIF-1α is a significant molecular pathogenetic factor in the development of fetoplacental dysfunction and intrapartum fetal death in preeclampsia.

Keywords: HIF-1a; placental dysfunction; preeclampsia.

First page

199

Last page

202

For citation:Zhabborova M.A., Akhmadzhonova G.M. - MOLECULAR AND PATHOGENETIC ASPECTS OF HIF-1Α INVOLVEMENT IN THE DEVELOPMENT OF INTRAPARTUM FETAL DEATH IN PREECLAMPSIA//New Day in Medicine 2(88)2026 199-202 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

  1. ACOG Practice Bulletin: Diagnosis and Treatment of Preeclampsia and Eclampsia. Issue 33. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;99:159-67. 10.1016/S0029-7844(01)01747-1.
  2. Sibay B, Decker G, Kupfermintz M: Preeclampsia. Lancet. 2005;365:785-97.
  3. Rescue Secretary. Technical Review: Prevention, Diagnosis, and Treatment of Preeclampsia/Eclampsia. 2007, Mexico, DF, 4
  4. Romero Arauz JF, Tena Alaves J: Epidemiology, classification and risk factors for the development of preeclampsia. Enfermedades hypertensivs del embarazo. Edited by: McGrawhill, Mexico. 2009; 1-15.
  5. Velasco ME, Navarrete ON: Maternal deaths in IMSS, 1991–2005. Cambial period. Rev Med Inst Mex Seguro Soc. 2006;44:121–8.
  6. Souza JP, Cecatchi JG, Fondes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Vojdyla D, Zavaleta N, Donner A, Velasco A, Batalha V, Valladares E, Kublickas M, Acosta A: Near maternal deaths and maternal mortality in the 2005 World Health Organization global survey on maternal and perinatal health. Bulletin of the World Health Organization. 2010;88:113-9. 10.2471/BLT.08.057828.
  7. Zhou Y, Damski CH, Fisher SJ: Preeclampsia is associated with a failure of human cytotrophoblasts to mimic the vascular adhesion phenotype. A cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99:2152-64. 10.1172/JCI119388.
  8. Maynard S, Epstein FH, Karumanchi SA: Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61-78. 10.1146/annurev.med.59.110106.214058.
  9. Semenza GL, Wang GL: Hypoxia-induced nuclear factor-2-associated protein synthesis (NIF-2) binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. // Mol Cell Biol. 1992;12:5447-54.
  10. Rajakumar A, Conrad K: Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. Biol Reprod. 2000;63:559-69. 10.1095/biolreprod63.2.559.

    file

    download